Conference Coverage

AVAHO Education Chair Mary Thomas on the AVAHO Meeting Program

Mary L. Thomas talks with Federal Practitioner about the meaning of precision and personalized medicine and the importance of focusing on the patient.


 

The Association of VA Hematology and Oncology will open the doors to its 2015 conference on Friday. The conference theme is “Precision & Personalized Medicine–Their role in Hematologic-Oncologic Care within VHA.” Recently, Federal Practitioner spoke with Mary L. Thomas, MS, CNS, AOCN, education chair, about the program for the meeting.

Eric Green, MD, PhD, director of the National Genome Research Institute at the National Institutes of Health, will deliver one of the keynote addresses on human genomics and precision medicine. The second keynote address will be from Betty Ferrell, PhD, MA, FAAN, FPCN, director and professor, associate director for nursing research at City of Hope. Dr. Ferrell will focus on the personal side of personalized medicine.

Check back soon for updates on the conference.

Recommended Reading

Prevalence of Prostate-Specific Antigen Testing Informed Consent Among Veteran Males Aged 55 to 69 Years
Federal Practitioner
Making Distress Screening Useful for Nursing and Social Work
Federal Practitioner
PSA Response Rates Far Exceeded Expectations in Treating Asymptomatic, Androgen-Resistant Prostate Cancer With Abiraterone
Federal Practitioner
Comparison of Initial Diagnosis and Treatment for Hepatocellular Carcinoma Between VA and Nonveteran Populations
Federal Practitioner
A Retrospective Evaluation of Outcomes in Veteran Patients With Agent Orange Exposure and Prostate Cancer
Federal Practitioner
Incident Chronic Kidney Disease Following Kidney Cancer Surgery
Federal Practitioner
The Efficacy of Abiraterone Pre-and Postdocetaxel and Sequential Use of Enzalutamide After Abiraterone in Veteran Patients With Metastatic Castration-Resistant Prostate Carcinoma
Federal Practitioner
Improving the Accuracy of Ordering and Reporting for Send-Out Laboratory Studies
Federal Practitioner
The Evaluation of Venous Thromboembolism/Adverse Drug Events in VA Loma Linda Oncology Patients on Warfarin vs Low Molecular Weight Heparin
Federal Practitioner
Did the FDA Black Box Warning Have Any Effect on Erythropoiesis-Stimulating Agent Use?
Federal Practitioner

Related Articles